ALBHF: AI 评分 45/100 — AI 分析 (4月 2026)

Alibaba Health Information Technology Limited operates a pharmaceutical e-commerce platform and provides healthcare services in Mainland China and Hong Kong. The company leverages its parent company's (Alibaba) technology and reach to deliver online pharmacy and digital healthcare solutions.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Alibaba Health Information Technology Limited operates a leading pharmaceutical e-commerce platform in China, offering prescription drugs, OTC medications, and healthcare services through online and offline channels, leveraging its connection to Alibaba's vast ecosystem to capture a significant share of the growing digital healthcare market.

ALBHF是做什么的？

Alibaba Health Information Technology Limited, formerly known as CITIC 21CN Company Limited, rebranded in September 2014 following its acquisition by Alibaba Group. The company has evolved into a comprehensive healthcare platform, operating primarily in Mainland China and Hong Kong. Its core business revolves around pharmaceutical direct sales and its pharmaceutical e-commerce platform. Through online stores on Tmall.com and offline pharmacy outlets, Alibaba Health provides a wide array of products, including prescription drugs, over-the-counter medications, nutritional supplements, and medical devices, catering to both business-to-customer (B2C) and business-to-business (B2B) segments. The company's e-commerce platform extends its offerings to include health food, sexual health products, contact lenses, and various medical and healthcare services. Alibaba Health also provides medical and healthcare services, such as medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and Traditional Chinese Medicine (TCM) consultations through multiple channels like Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. Beyond its core e-commerce activities, Alibaba Health engages in tracking services, operates network hospitals, and provides healthcare-related internet information and technical services.

ALBHF的投资论点是什么？

Alibaba Health presents a compelling, albeit risky, investment opportunity within China's rapidly expanding digital healthcare market. The company's strong connection to Alibaba Group provides a significant competitive advantage, driving user acquisition and platform growth. With a P/E ratio of 31.50 and a profit margin of 5.8%, the company demonstrates profitability, but investors should be aware of the high beta of 1.72, indicating higher volatility compared to the market. Growth catalysts include the increasing adoption of online pharmacies and digital healthcare services in China, driven by convenience and accessibility. Key risks involve regulatory uncertainties in the Chinese healthcare sector and competition from other established players. The company's ability to maintain and expand its market share, while navigating the complex regulatory landscape, will be crucial to its long-term success.

ALBHF在哪个行业运营？

Alibaba Health operates within China's rapidly growing digital healthcare market. The industry is characterized by increasing adoption of online pharmacies, telemedicine, and digital health services, driven by factors such as increasing internet penetration, rising healthcare costs, and government support for digital health initiatives. The competitive landscape includes traditional pharmaceutical companies, online pharmacies, and technology companies entering the healthcare space. Alibaba Health benefits from its association with Alibaba Group, giving it a strong competitive advantage in terms of brand recognition, technology infrastructure, and user base.

Medical - Pharmaceuticals

Healthcare

ALBHF有哪些增长机遇？

Expansion of Online Pharmacy Business: The increasing adoption of online pharmacies in China presents a significant growth opportunity for Alibaba Health. The market for online pharmacies is projected to reach billions of dollars in the coming years, driven by convenience and accessibility. Alibaba Health can leverage its existing e-commerce platform and logistics network to capture a larger share of this market. The timeline for this growth is ongoing, with continuous expansion expected over the next 3-5 years.
Growth in Telemedicine and Digital Health Services: The demand for telemedicine and digital health services is growing rapidly in China, driven by factors such as increasing healthcare costs and a shortage of healthcare professionals. Alibaba Health can capitalize on this trend by expanding its telemedicine offerings and developing new digital health services, such as remote monitoring and chronic disease management. This growth is expected to accelerate over the next 2-3 years.
Penetration into Lower-Tier Cities and Rural Areas: While Alibaba Health has a strong presence in major cities in China, there is significant potential to expand into lower-tier cities and rural areas. These areas have a large population and increasing demand for healthcare services. Alibaba Health can leverage its e-commerce platform and logistics network to reach these underserved markets. Expansion into these regions is expected to unfold over the next 3-5 years.
Development of New Healthcare Products and Services: Alibaba Health can drive growth by developing new healthcare products and services that cater to the evolving needs of its customers. This could include developing new over-the-counter medications, nutritional supplements, and medical devices. It could also involve offering new healthcare services, such as personalized medicine and genetic testing. New product and service development is an ongoing process.
Strategic Partnerships and Acquisitions: Alibaba Health can accelerate its growth through strategic partnerships and acquisitions. This could involve partnering with other healthcare companies to expand its product and service offerings or acquiring companies with complementary technologies or market access. Strategic partnerships and acquisitions are expected to occur opportunistically over the next few years.

Market capitalization of $10.61 billion reflects significant investor interest in the company's growth potential.
P/E ratio of 31.50 indicates a premium valuation, suggesting high expectations for future earnings growth.
Profit margin of 5.8% demonstrates profitability in a competitive market.
Gross margin of 24.5% reflects the company's ability to manage costs effectively.
Beta of 1.72 indicates higher volatility compared to the market, suggesting a riskier investment profile.

ALBHF提供哪些产品和服务？

Operates an online pharmaceutical e-commerce platform.
Sells prescription drugs, over-the-counter medications, and health-related products.
Provides medical and healthcare services, including medical checkups and consultations.
Offers telemedicine and digital health services.
Operates network hospitals.
Provides healthcare-related internet information and technical services.

ALBHF如何赚钱？

Generates revenue from the sale of pharmaceutical products and healthcare services.
Operates an e-commerce platform, connecting customers with healthcare providers and products.
Leverages its relationship with Alibaba Group to drive user acquisition and platform growth.

Individual consumers seeking pharmaceutical products and healthcare services.
Businesses purchasing pharmaceutical products for resale or use in their operations.
Healthcare providers seeking to expand their reach and offer digital health services.

Strong brand recognition and reputation.
Established e-commerce platform and logistics network.
Relationship with Alibaba Group provides access to a large user base and technology infrastructure.
Extensive product and service offerings.

什么因素可能推动ALBHF股价上涨？

Ongoing: Expansion of online pharmacy business driven by increasing internet penetration in China.
Ongoing: Growth in telemedicine and digital health services due to rising healthcare costs and demand for remote care.
Upcoming: Potential regulatory approvals for new pharmaceutical products or healthcare services.
Upcoming: Strategic partnerships or acquisitions to expand product offerings and market reach.
Ongoing: Increasing demand for healthcare services in lower-tier cities and rural areas.

ALBHF的主要风险是什么？

Ongoing: Regulatory changes in China's healthcare sector could impact the company's operations and profitability.
Ongoing: Intense competition from other players in the digital healthcare market.
Potential: Economic slowdown in China could reduce consumer spending on healthcare products and services.
Potential: Cybersecurity risks could compromise the company's data and systems.
Ongoing: Reliance on Alibaba Group exposes the company to risks associated with its parent company's business and reputation.

ALBHF的核心优势是什么？

Strong brand recognition and reputation
Established e-commerce platform and logistics network
Relationship with Alibaba Group
Extensive product and service offerings

ALBHF的劣势是什么？

Reliance on Alibaba Group
Exposure to regulatory risks in China
Intense competition in the digital healthcare market
OTC listing may limit investor access

ALBHF有哪些机遇？

Expansion of online pharmacy business
Growth in telemedicine and digital health services
Penetration into lower-tier cities and rural areas
Development of new healthcare products and services

ALBHF面临哪些威胁？

Regulatory changes in China
Increased competition from other players
Economic slowdown in China
Cybersecurity risks

ALBHF的竞争对手是谁？

BeiGene, Ltd. — Focuses on developing and commercializing innovative cancer therapies. — (BMXMF)
China Eastern Airlines Corporation Limited — Unclear relevance as it's an airline; potentially incorrect peer data. — (CHEOY)
Fosun International Holdings Ltd — Diversified conglomerate with healthcare investments. — (FSPKF)
Ocumension Therapeutics — Focuses on ophthalmic pharmaceutical products. — (OCPNF)
Sartorius AG — Provides bioprocessing solutions and lab equipment. — (SARTF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Difan Shen
Headquarters: Causeway Bay, HK
Employees: 1,422
Founded: 2018

AI Insight

AI analysis pending for ALBHF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Alibaba Health Information Technology Limited do?

Alibaba Health Information Technology Limited operates as a key player in China's digital healthcare landscape. It primarily focuses on running a comprehensive pharmaceutical e-commerce platform, offering a wide range of prescription and over-the-counter drugs, along with various health-related products. Beyond its e-commerce activities, the company provides diverse medical and healthcare services, including online medical consultations, health checkups, and access to traditional Chinese medicine. By leveraging its connection to Alibaba's vast ecosystem, Alibaba Health aims to provide convenient and accessible healthcare solutions to a large customer base.

What do analysts say about ALBHF stock?

Due to the limited information available, a comprehensive analyst consensus on ALBHF stock cannot be provided. However, considering its position in the growing Chinese digital healthcare market and its association with Alibaba Group, analysts likely view the company as having significant growth potential. Key valuation metrics, such as the P/E ratio of 31.50, suggest that investors have high expectations for future earnings. However, the high beta of 1.72 also indicates a higher level of risk compared to the overall market. Investors should conduct their own thorough research and consider their risk tolerance before investing in ALBHF.

What are the main risks for ALBHF?

Alibaba Health faces several key risks. The regulatory environment in China's healthcare sector is subject to change, which could impact the company's operations and profitability. Intense competition from other players in the digital healthcare market poses a threat to its market share. An economic slowdown in China could reduce consumer spending on healthcare products and services. Cybersecurity risks could compromise the company's data and systems. Finally, the company's reliance on Alibaba Group exposes it to risks associated with its parent company's business and reputation. These risks should be carefully considered by potential investors.